Actively Recruiting
Long-Term Study of First-Line Tislelizumab and Chemotherapy in Advanced Squamous NSCLC Patients from the RATIONALE-307 Trial
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-03-27
109
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to collect long-term survival data from patients with advanced squamous non-small cell lung cancer NSCLC who received first-line treatment with tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to gather more evidence on the long-term benefits of immunotherapy for these patients and to identify those who may gain greater clinical advantage from this treatment approach. The study is observational and involves no new interventions. It focuses on patients who participated in the RATIONALE-307 trial and were alive at the completion of that study. There are no additional treatments or experimental procedures in this follow-up period. Participants will have their overall survival data collected retrospectively, defined as the time from randomization in the RATIONALE-307 trial until death from any cause occurring on or before December 31, 2025. The study will analyze this data to better understand long-term outcomes. Since this is a retrospective study, there is no active involvement or new assessments required from participants beyond data collection.
CONDITIONS
Brief Title
A Retrospective Real-World Study Based on RATIONALE-307
Research Team
Z
Zhijie Wang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
